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Abstract
 Background—Acute and chronic exposures to widely used organophosphorus (OP) 
insecticides are common. Children’s detoxification mechanisms are not well developed until 
several years after birth. The increased cases of neurodevelopmental disorders in children, together 
with their increased susceptibility to OP neurotoxicity cannot be explained by genetic factors 
alone but could be related to gene-environment interactions. Paraoxonase-1 (PON1) is an enzyme 
that can detoxify OPs but its catalytic efficiency for hydrolysis to certain OPs is modulated by the 
Q192R polymorphism.
 Findings—Studies in animals have provided important information on the role of PON1 in 
protecting against gestational and postnatal toxicity to OPs. The PON1Q192 allele is less efficient 
hydrolyzing certain OPs than the PON1R192 allele. Maternal PON1 status (PON1 activity levels, 
the most important measurement, and functional Q192R phenotype) modulates the detrimental 
effects of exposure to the OP chlorpyrifos oxon on fetal brain gene expression and biomarkers of 
exposure. Epidemiological studies suggest that children from mothers with lower PON1 status that 
were in contact with OPs during pregnancy tend to show smaller head circumference at birth and 
adverse effects in cognitive function during childhood.
 Conclusion—Infants and children are vulnerable to OP toxicity. The detrimental 
consequences of OPs on neurodevelopment can lead to future generations with permanent 
cognitive problems and susceptibility to develop neurodegenerative diseases. Improved methods 
using mass spectrometry to monitor OP-adducted biomarker proteins are needed and will be 
extremely helpful in early life biomonitoring, while measurement of PON1 status as a biomarker 
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of susceptibility will help identify mothers and children highly sensitive to OPs. The use of 
adductomics instead of enzymatic activity assays for biomonitoring OP exposures have proved to 
provide several advantages, including the use of dried blood spots, which would facilitate 
monitoring newborn babies and children.
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 INTRODUCTION
While some organophosphorus (OP) insecticides are being phased out in the United States, 
they are still widely used in developing countries. It is estimated that each year, there are 3 
million insecticide poisonings worldwide with 220,000 deaths.1 About 33 million pounds of 
OP insecticides were used in 2007 in the United States,2 mostly for the control of pests in 
agricultural settings. According to the American Association of Poison Control Centers’ 
National Poison Data System (NPDS), about 32% of the OP insecticide exposures reported 
in 2013 involved children.3 Routes of OP exposure include ingestion, inhalation and dermal 
contact in occupational, residential and non-residential settings. The frequency of 
neurodevelopmental disorders in children seem to be increasing worldwide. Developmental 
disabilities include specific learning and intellectual disabilities, autism, and attention deficit 
hyperactivity disorders.4 Genetic factors only explain up to 40% of the neurodevelopmental 
disabilities reported. Growing evidence suggests that environmental exposures in 
combination with individual genetic susceptibility could trigger these disorders. This review 
will focus on gene-environment interactions important for modulating exposures to specific 
OP insecticides in early life.
More than six decades ago, the plasma enzyme paraoxonase-1 (PON1) was shown to 
hydrolyze toxic metabolites of OP insecticides.5,6 Early observations noted that species with 
high plasma paraoxonase levels were more resistant to parathion exposures than species with 
low plasma paraoxonase levels.7,8 Thus, for more than 4 decades it was thought that PON1 
could protect against exposure to parathion as well as other OP compounds.9 As noted 
below, experiments in mice with genetically modified PON1 genes, showed that human 
PON1 modulates sensitivity primarily to chlorpyrifos (CPS) and diazinon (DZS), especially 
for direct exposure to their oxon forms present in most, if not all exposures.9–12 It is worth 
noting that all of the safety studies for chlorpyrifos oxon (CPO) have been carried out with 
highly pure, less toxic parent compound CPS.13 More valid safety studies should be carried 
out with exposures containing a percentage of CPO representative to that found in actual 
exposures.
Several important questions arise from these early observations. 1) Does human plasma 
PON1 protect against exposure to specific OP compounds? 2) If so, is there genetic and or 
developmental variability in the plasma levels of PON1 among individuals? 3) Is there 
developmental regulation of plasma PON1 levels in early life? 4) Is a mother’s plasma 
PON1 protective against OP exposures for her fetus(s)? In this review, we examine these 
four important questions.
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The question of the ability of PON1 to protect against OP exposure was directly tested in 
1956 by Main14 in experiments where he injected partially purified rabbit PON1 into rats 
increasing their A-esterase activity four to five times and decreasing the toxicity of injected 
paraoxon (PO). This observation was repeated and extended to the effects of PON1 on CPO 
toxicity by Costa et al.15 Many further experiments were carried out in mice showing PON1 
protection against CPO and its parent compound CPS. A study in mice injected with rabbit 
PON1 clearly demonstrated that high levels of PON1 protected against exposure to both 
CPO and CPS.16 The effects of low levels of plasma PON1 were examined in PON1 
knockout (PON1−/−) mice which were shown to be dramatically sensitive to CPO17 and 
diazoxon (DZO), with less dramatically increased sensitivity to their respective parent 
compounds CPS and DZS.9 Surprisingly, the PON1−/− mice showed no increased sensitivity 
to PO,9 indicating that mouse PON1 does not have a role in detoxifying PO in vivo, even 
though PON1 had been named for its ability to hydrolyze PO in vitro. Resistance to CPO 
and DZO could be restored by the injection of purified human PON1192 alloforms, with both 
alloforms (Q and R) providing equal protection against DZO and the PON1R192 alloform 
providing better protection against CPO, in agreement with the respective catalytic 
efficiencies for hydrolysis of these two OPs by each PON1192 alloform. Also in agreement 
with the lack of increased sensitivity of the PON1−/− mice to PO, injection of neither human 
PON1192 alloform protected against PO exposure in contrast to rabbit PON1. Injection into 
PON1−/− mice of engineered recombinant human PON1 (rHuPON1) with lysine replacing 
arginine or glutamine at position 192 provided further evidence for the importance of high 
catalytic efficiency in PON1 protecting against OP exposure.18 The rHuPON1K192 when 
injected into PON1−/− mice protected against 2 or 3 LD50 levels of exposures of the 
PON1−/− mice to DZO. The rHuPON1K192 has higher catalytic efficiency for the hydrolysis 
of DZO, CPO and PO than the native PON1192 Q or R alloforms and was designed based on 
the high catalytic efficiency of rabbit PON1 for hydrolysis of CPO.
These experiments clearly demonstrate the importance of PON1 in protecting against CPS 
and DZS exposures, especially to the oxon forms present in these exposures.9 They also 
point out the potential for treating acute, life-threatening OP exposures with injections of 
rHuPON1 or engineered rHuPON1, which will be necessary for treating exposures to 
parathion/PO.9,16,18
Since PON1 plays an important role in resistance to exposure by at least two commonly 
used OP insecticides, the role of genetic and developmental variability become important 
questions related to early life exposures. PON1 is a polymorphic enzyme. Early studies in 
the 1960s and 1970s used PO as the substrate to measure PON1 activity in human 
populations. Most of them reported a high variability of PON1 activity between individuals, 
showing either a bimodal or trimodal distribution of serum PON1 activity levels19 leading to 
the suggestion that the paraoxonase activity of PON1 exhibited a genetic polymorphism.20 
Several assays were developed to examine this polymorphic distribution of PON1 activity, 
all used PO as a substrate under varying conditions of pH, salt concentration, calcium, buffer 
composition and EDTA. Interestingly, this polymorphic distribution was not observed when 
using phenyl acetate as a substrate. Taking advantage of these substrate differences, an 
improved PON1 phenotype resolution was achieved by measuring PON1 activity with the 
two different substrates PO and phenyl acetate. This two-substrate assay/analysis, pioneered 
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in La Du’s laboratory21 clearly resolved individuals with low PON1 activities by plotting 
rates of PO (with high salt in the assay) vs. phenyl acetate, however, the intermediate and 
high metabolizers were not resolved by this two-dimensional analysis. Cloning and 
sequencing of the human PON1 gene revealed two major coding polymorphisms, L55M and 
Q192R.22 The basis of the high vs. low rates of PO hydrolysis was subsequently shown to be 
determined by the Q192R polymorphism with the PON1R192 alloform hydrolyzing PO much 
more efficiently than the PONQ192 alloform.23,24 Further improvement of this two-substrate 
analysis, referred to as PON1 status,25 involved plotting rates of DZO hydrolysis vs. PO 
hydrolysis.26,27 This assay clearly resolved all three PON1192 phenotypes (Q/Q, Q/R and 
R/R). Results obtained from PON1 status analyses show inter- and intra-assay 
reproducibility, although samples should be analyzed within 2 years from collection.28 A 
version of the PON1 status analysis that makes use of non-highly-toxic substrates has 
recently been developed to reduce exposure of laboratory personnel to the highly toxic 
oxons of PO and DZO.29
A typical PON1 status plot (for 704 individuals) is shown in Figure 1.30 This plot also shows 
the importance of the functional analysis of the two-dimensional PON1 status plot. The 
activity level for each individual is revealed by the plot which also identified 4 individuals 
where the functional analysis was discrepant from the DNA single nucleotide polymorhipsm 
(SNP) analysis. Sequencing the PON1 gene from these individuals revealed the defect in one 
allele in each, where the individuals genotyping as PON1192 heterozygotes functionally 
showed only one active PON1 alloform. It is important to note that for epidemiological 
studies, a SNP analysis provides only information about the PON1 SNPs present in the 
individual’s genome and no information about the PON1 activity levels, the most important 
factor in determining risk of exposure or disease. One could characterize all ≈200 SNPs 
(Fig. 2) and not be able to predict PON1 activity level. We emphasize this point since many 
dozens of epidemiological studies have been carried out using only an analysis of SNPs, 
ignoring the most important factor affecting risk, which is PON1 activity level.31
The question of developmental regulation of PON1 activity levels has been examined in at 
least two recent studies. Cole et al. reported that PON1 levels of newborns are approximately 
one third to one fourth the levels of adults. It takes between 6 months and two years for the 
PON1 levels in babies to reach adult activity levels.32 On the other hand, plasma PON1 
activity reaches adult levels in mice at three weeks of age.33 When the human PON1Q192 
and PON1R192 transgenes, including their respective 5’ regulatory regions, are expressed in 
PON1−/− mice, the time course is the same as observed in wild type mice with activity 
peaking at ≈3 weeks of age, indicating a strong conservation of PON1 regulatory elements 
between humans and mice.32 A study carried out in collaboration with the University of 
California Children’s Health Study Program showed a large variability of PON1 activity 
levels among both mothers and newborns (Fig. 3).34 The average PON1 activity levels in the 
newborns were comparable with the PON1 levels in the PON1 transgenic mice allowing for 
the prediction of the relative sensitivity to CPO and DZO. The predicted range of sensitivity 
for CPO exposure between the newborn with the lowest PON1 activity level and the mother 
with the highest PON1 activity level was 131- to 164-fold and for DZO ≈65-fold. A major 
concern would be for the mothers with low PON1 activity levels to protect their fetuses from 
exposure to these OP compounds. The data supporting these concerns are discussed below.
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 ROLE OF PON1 IN PRE- AND POSTNATAL OP EXPOSURES IN ANIMAL 
STUDIES
OP insecticides are developmental neurotoxicants that can lead to permanent brain damage. 
Concern for prenatal and postnatal exposure to OP insecticides such as CPS and their 
potential effect in neurodevelopment and neurotoxicity has prompted many studies on OP 
exposures in dams, fetuses and pups. Several in vitro studies have shown potential 
neurodevelopmental effects of CPO at levels that do not inhibit acetylcholinesterase 
(AChE).35 This is of special interest, as chronic low-level environmental OP exposures are 
common.
PON1, one of the main CPO detoxifying enzymes, is modulated by age. As mentioned 
above, studies of PON1 expression during development in transgenic mice expressing either 
human PON1Q192R alloforms (tgHuPON1Q192 and tgHuPON1R192) indicated that PON1 
activity is low at birth and it plateaus at 3 to 4 weeks of age.32 This finding was in agreement 
with previous studies in wild type mice and rats,33,36 suggesting that the developing brain 
may be more susceptible to the toxic effects of certain OPs. Creation of the PON1−/− mouse 
was key to demonstrate the role of PON1 in detoxification of certain OPs such as CPO and 
DZO, and their parent compounds.9,17 The “humanized” tgHuPON1 mice generated on the 
PON1−/− background provided a better understanding of the effect of PON1 Q192R 
polymorphism in OP exposures in vivo. As observed in studies injecting the two PON1 
alloforms in PON1−/− mice,9 adult transgenic mice carrying only the PON1Q192 allele were 
more sensitive to CPS and CPO exposure than tgHuPON1R192 mice.37
There are very few studies on pre- and postnatal effects of OP exposures in relation to 
PON1. In a study of oral gestational exposure to CPS in rats from gestational day (GD) 14 to 
GD18, the authors concluded that fetal brain total cholinesterase [AChE and 
butyrylcholinesterase (BChE)] was able to recover faster between dosages than maternal 
brain total cholinesterase.38 As expected, PON1 activity in fetal tissues (liver and placenta) 
was quite low compared to the maternal tissues, providing little potential for CPS 
detoxification in rat fetuses by PON1. A similar study using C57BL/6 dams chronically 
exposed to CPS via subcutaneous injection from GD6 to GD17 also showed fetal resistance 
to CPS toxicity, with fetal brain AChE less inhibited than maternal brain AChE.39 In order to 
study the neurotoxic effects in fetuses and the protective effect of maternal PON1 Q192R 
polymorphism in repeated CPO exposures, a more recent gestational study has been 
published using wild type, PON1−/−, tgHuPON1Q192 and tgHuPON1R192 mice.40 Pregnant 
female mice were dermally exposed from GD6 to GD17 to doses of CPO that caused minor 
inhibition of maternal brain AChE in wild type mice. Maternal biomarkers of OP exposure 
(plasma BChE, carboxylesterase, red blood cell acylpeptide hydrolase and brain AChE) 
showed significantly decreased activity, independently of the mouse strain tested (except for 
brain AChE activity in wild type dams). However, only fetal plasma BChE activity seemed 
to be affected by CPO toxicity, despite reported fast recovery of cholinesterases in fetuses.38 
These effects seemed to be modulated by maternal PON1 activity levels and dependent on 
the maternal PON1 Q192R polymorphism, as fetuses had extremely low plasma PON1 
activity. A much more rapid CPO detoxification in maternal plasma could prevent CPO from 
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reaching fetal brain and inhibiting AChE. Conversely, studies reporting some fetal brain 
AChE inhibition used CPS,38,39 which is first metabolized by cytochrome P450s to the 
reactive CPO in maternal and fetal tissues (CPS can cross the placenta) and then detoxified.
As predicted from other studies,9,37 fetuses of PON1−/− dams were the most susceptible to 
chronic CPO exposure, followed by fetuses from tgHuPON1Q192 dams. These findings were 
supported by gene expression data obtained in this same study. Following CPO exposure, 
brain from fetuses of tgHuPON1Q192 dams, compared to fetal brain from tgHuPON1R192 
dams, were enriched in gene sets related to the mitochondrial respiratory chain, lipid 
metabolism, cell cycle, vesicle membranes, and neurotransmission by glutamate receptors, 
among many others.40 Therefore, this study demonstrated that maternal PON1 status could 
modulate the effects of gestational exposure to CPO on fetal brain gene expression and 
biomarkers of exposure. An earlier study conducted in C57BL/6 mice reported similar gene 
sets affected in fetal brain resulting from CPS-exposure to dams.39
Studies on neonatal OP exposures have been very important in demonstrating the role of 
PON1 status in determining susceptibility to developmental neurotoxicity. Repeated daily 
exposure of wild type, PON1−/−, tgHuPON1Q192 and tgHuPON1R192 mice to CPO from 
postnatal day (PND) 4 to PND21 resulted in changes in cerebellar gene expression, body 
weight and neurobehavioral deficits.41,42 In humans, PND4 to PND21 would parallel the 
neurodevelopmental period comprised between late gestation and the first two years of life. 
A 2.5-fold difference in resistance to CPO between wild type and PON1−/− mice was 
already observable in 4-day-old mice.41 Although the doses of CPO used in that study where 
low and not lethal to PON1−/− mice, chronic exposure to CPO reduced brain AChE activity 
more significantly in the PON1−/− and tgHuPON1Q192 mice, strains that have lower capacity 
of CPO detoxification. These two strains of mice also showed the same cerebellar pathways 
affected by exposure, mostly related to mitochondrial dysfunction and oxidative 
phosphorylation,41 consistent with other studies that have associated oxidative stress with 
OP exposures.43 Extensive neurobehavioral testing of the CPO-exposed PON1−/− mice only 
showed changes in startle latency and dose-related transient hyperkinesis.42 Perhaps the 
effects of CPO exposure in mice are age-dependent, or alternative neurobehavioral tests 
assessing other brain neurotransmitter systems and social interactions should have been 
tested. Thus, PON1 protection against CPO toxicity during postnatal development is 
determined by the level of PON1 expression, with juvenile mice with low PON1 status 
(tgHuPON1Q192) being more susceptible to CPO toxicity than tgHuPON1R192.
 PON1 AS A BIOMARKER OF SUSCEPTIBILITY TO 
NEURODEVELOPMENTAL EFFECTS
Children are particularly susceptible to environmental toxicants. OP insecticides such as 
CPS, the most used OP insecticide in the USA, can reach fetal tissues by crossing the 
placenta, with exposure continuing after birth through breast milk.4 Of note is that the 
blood-brain barrier is not completely developed until around the first year of life and, 
therefore, does not protect against chemicals crossing into the brain. There have been 
numerous studies on the effects of CPS in pregnant women and children, most of them 
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accurately reviewed by Eaton and colleagues.35 As this review focuses on PON1, in this 
section we will limit the studies discussed to those that included assessment of both PON1 
genotype and phenotype, as genotype alone is uninformative.31,34
Given the role of PON1 in protecting against OP exposures and the lower PON1 levels at 
birth, the study of the role of PON1 in OP exposures and related outcomes during pregnancy 
and childhood continues to be the focus of intense research. The lower PON1 levels in 
children were first reported in 1963.44 However, since we now know that the serum 
arylesterase activity is catalyzed by PON1,18,24 the relationship of PON1 levels with 
neurochemical and neurobehavioral changes following OP exposures was not evidenced 
until recently.
Several reports on a multiethnic birth cohort study at the Mount Sinai Medical Center (New 
York City) have documented effects on fetal growth and neurodevelopment from in utero 
exposures to CPS in relationship with maternal PON1 activity and genotype. In their first 
study, smaller head circumferences were reported in babies from mothers with low PON1 
activity, compared to the offspring from mothers with higher PON1 arylesterase activity or 
non-exposed mothers.45 A later study by the same investigators on prenatal exposures to 
OPs and other pesticides in another cohort in the same geographical area confirmed their 
previous finding of lower PON1 arylesterase activity leading to decreased head 
circumferences in babies.46 In addition, they also found statistically significant relationships 
between certain urinary dialkylphosphate metabolites (DAPs), low PON1 status (low PON1 
arylesterase activity and PON1QQ192 genotype), and decreased birth weight and birth length. 
They also assessed abnormalities in neonatal behavior and primitive reflexes with the 
Brazelton Neonatal Behavioral Assessment Scale, an index to assess newborn’s abilities. 
There was an increased number of abnormal primitive reflexes in neonates from mothers 
with low PON1 arylesterase activity and high DAP metabolite levels during pregnancy.47 In 
a follow-up study of the cohort at ages 1–2 and 6–9 years old, the authors evaluated the 
impact of early life exposures in development.48 In this case they used the Bayley Scales of 
Infant Development, which provides age-standardized norms of mental and psychomotor 
development. The results of years 1–2 were somewhat contradictory in terms of maternal 
PON1192 genotype, probably due to sample size and heterogeneous race/ethnicity. However, 
their findings suggested that prenatal exposure to OPs (estimated by maternal urinary DAPs) 
had a detrimental effect on perceptual reasoning (cognitive development) in 1–2 year old 
infants. This evidence was stronger in 6–9 year old children of mothers homozygous for the 
PON1Q192 polymorphism. No effect of PON1 arylesterase activity from maternal blood or 
cord blood on the neurodevelopmental assessment performed was noted. This was the first 
study to examine a possible association between PON1 Q192R genotype and 
neurobehavioral end points in children.
The Center for the Health Assessment of Mothers and Children of Salinas (CHAMACOS) 
study is a longitudinal birth cohort study from an agricultural Mexican-American 
community from the Salinas Valley (CA). Farmworker mothers had been exposed to 
relatively high levels of OP pesticides during pregnancy, as assessed by urinary DAP 
metabolites. When measuring PON1 status in mothers and their babies, at birth, children’s 
PON1 levels were one-fourth the level of the mothers, with a predicted sensitivity to DZO 
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exposure of 26-fold vs.14-fold among the mothers.34 The calculated range of sensitivity to 
CPO exposure was of 131–164-fold between the PON1QQ192 newborn with lowest PON1 
status and the PON1RR192 mother with highest PON1 status. That was the first study to 
assess PON1 status in a cohort of mothers and babies exposed to OPs. Prenatal maternal 
urinary DAPs were associated with detrimental pervasive and mental development in 
children at age of 2, as measured with the Bayley Scales of Infant Development.49 
Decreased mental development scores appeared to be related to the child’s promoter 
PON1-108T allele, while psychomotor developmental scores in PON1QQ192 children were 
inversely associated with urinary DAP levels.50 At ages 5 to 7, full-scale IQ scores tended to 
be lower in PON1-108TT children and in children from mothers with higher DAP levels and 
lower PON1 arylesterase activity during pregnancy, with the latter also showing lower verbal 
comprehension.51 Altogether, these results suggest that PON1 genotype and low activity 
may be related to adverse cognitive functioning in vulnerable children, i.e. children from 
mothers with low PON1 activity exposed to OPs during pregnancy.
 BIOMONITORING OF ORGANOPHOSPHORUS EXPOSURES
Primary routes of OP exposure in the United States are through food consumption and spray 
drift in agricultural communities.10,52 While the states of Washington and California have 
ongoing biomonitoring programs of their agricultural workers, who can potentially suffer 
acute occupational exposures to the insecticides sprayed, there are a lack of methods 
sensitive enough to quantify non-occupational low level chronic OP exposures in the general 
population. Biomonitoring of acute and chronic environmental exposures is especially 
important for pregnant women and children, which are more vulnerable to the effect of 
neurotoxicants. Therefore, improved assessment of children’s exposures is highly needed.53 
Upon entering the human body, the parent OP organophosphorothioates are either detoxified 
by specific cytochrome P450s (and eliminated in the urine) or are converted to their highly 
toxic oxon forms (Fig. 4). The highly toxic oxons interact with serine active-site enzymes 
(e.g. AChE and BChE) creating a covalent bond with their active site serine that ages to an 
irreversible inhibitor of the enzyme. The adducted protein is stable and will remain in 
circulation until degradation, which depends on the protein’s half-life in circulation (11 days 
for plasma BChE and 33 days for red blood cell AChE). The oxons can also undergo 
spontaneous or enzymatic (i.e. PON1) hydrolysis resulting in the formation of DAP 
metabolites and an OP-specific leaving group. These metabolites do not show inhibitory 
properties and are eliminated in the urine.
Urinary DAP metabolites and cholinesterase enzymatic inhibition assays are the most 
common methods used for biomonitoring OP exposures.54 The two approaches offer 
advantages and disadvantages. Measurement of six DAP metabolites has been used to assess 
exposure of at least 28 OPs and is not an invasive method since it uses urine samples.55 
However, OP metabolites have short half-lives, ranging between 24 and 48 h, the OP or 
mixture of OPs involved in the exposure may form the same metabolites during hydrolysis 
and, therefore, the OP of exposure cannot be distinguished, and the metabolites cannot be 
discriminated from direct environmental exposure to non-toxic OP degradation products, 
which would result in overestimation of the exposure.54 As OPs target cholinesterases, 
among other serine hydrolases, inhibition of their activity in blood has been used for many 
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years as a surrogate to estimate the level of brain AChE inhibition. Inhibition of plasma 
BChE is one of the early biomarkers of OP exposure commonly used. The Ellman 
colorimetric enzymatic assays,56 which use red blood cells to determine AChE activity (with 
acetylthiocholine as substrate) or plasma for BChE activity (with butyrylthiocholine as 
substrate), are quite accurate, reliable and inexpensive. Although used for monitoring 
agricultural workers, the drawbacks of these assays are significant. The requirement of a pre-
exposure sample to be used as the individual’s baseline activity, the high intra- and inter-
individual variability and the inability to assess chronic low-level exposures that usually 
cause no cholinesterase inhibition are some of the disadvantages of the Ellman assays.54 A 
more accurate method for biomonitoring OP exposures is needed. An ideal biomonitoring 
protocol should accurately quantify exposures and provide some information about the OP 
compound, should be sensitive enough to monitor low level exposures, should be 
automatable and reproducible, and should require samples obtained through the least 
invasive route possible. In recent years, a focus on mass spectrometry (MS) as a tool for 
biomonitoring OP exposures has emerged.57 MS provides high sensitivity methods for 
targeting posttranslational modifications in proteins, including OP adducts. A myriad of 
biological processes result in adducted proteins and DNA, so in the recent years, the general 
study of adducts on biological molecules has been termed adductomics. Mass spectrometric 
analyses provide significant improvements since they can target any biomarker of OP 
exposure, not just the cholinesterases. Furthermore, proteins are very abundant, their half-
lives are much longer than those of urinary metabolites, and baseline activity measurements 
are not necessary.57 Although blood collection adductomics protocols is invasive and 
requires the sample to be processed and stored properly, the high sensitivity provided by MS 
has been demonstrated in preliminary experiments to provide adequate sensitivity for 
quantifying OP exposures from dried blood spots (Marsillach et al. manuscript in 
preparation). Dried blood spot samples are much easier to collect from finger sticks as well 
as easier to ship and archive. They should also allow for analysis of OP exposures from 
archived dried blood spots from newborn heel sticks.
 CONCLUSIONS AND FUTURE DIRECTIONS
Early life exposures have important effects on brain development that can lead to permanent 
damage, affecting the children’s future development in society and increasing their 
susceptibility to develop neurodegenerative diseases. Genetic variability of the PON1 gene 
and the resulting effects on protein structure and levels have provided an early, well-
characterized example of gene-environment interaction. All of the early research examined 
the role that PON1 played in modulating exposures to OP insecticides. Cloning and 
characterizing the PON1 cDNA along with purifying the two Q192R alloforms of PON1 
allowed for the determination of the effects of this coding region polymorphism on the 
catalytic efficiency of OP hydrolysis. The development of the PON1 genetically variable 
mice has provided an invaluable asset for understanding the physiological function of 
PON1.17,37 For many years, it was thought that high metabolizers of PO would be resistant 
to exposures to parathion/PO, however, experiments from our laboratory showed this not to 
be the case and demonstrated the importance of high catalytic efficiency for determining 
whether PON1 could protect against specific exposures.9 These experiments showed that the 
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genetic variability in PON1 governed primarily sensitivity to the oxons of CPS and DZS 
with some protection afforded to exposures to the respective parent 
organophosphorothioates. These experiments clearly pointed out that hydrolysis of OPs with 
in vitro assays was not a good indicator of the ability of PON1 to protect against exposure. 
PO and the nerve agents soman and sarin provide good examples of this point. The 
development of a protocol for generating native recombinant human PON1 (rHuPON1) from 
an E. coli expression system allowed for the characterization of the protective capacity of 
PON1 under physiological conditions and at the same time demonstrated the potential to 
make use of rHuPON1 as a therapeutic for treating OP exposures.
Another physiological function of PON1 in preventing cardiovascular disease came to light 
with the discovery by Mackness and colleagues that PON1 on the high-density lipoprotein 
particles was responsible for preventing the oxidation of low-density lipoprotein particles.58 
This observation initiated many studies on the relationship of PON1 genetic variability to 
various oxidative stress-related diseases. This subject is not covered in this review, but is 
worth mentioning for readers who would like to follow up other gene-environment 
interactions involving genetic variability of PON1. These studies also emphasize the 
importance in epidemiological studies of examining PON1 status, which reveals the activity 
of PON1 as well as the Q192R phenotype of individuals. Studies that include PON1 status 
have found that low PON1 activity levels are a risk factor not only for OP exposure but also 
for cardiovascular disease.59–61 Studies that examine only SNPs are missing the most 
important measure of risk, the activity levels of PON1, and have often led to inconclusive 
results.31 The assays for determining PON1 status are high throughput and, therefore, 
convenient for use in most laboratories.
Another important point to note in summarizing PON1 gene-environment interactions in 
early life exposures is the developmental variability of PON1 where newborns have much 
lower PON1 levels (also variable among infants) than adults and are thereby more sensitive 
to exposures for which PON1 modulates risk.
Epidemiological studies with appropriate measurement of PON1 status as a biomarker of 
susceptibility coupled with accurate measures of exposures are still needed. The focus on 
MS analysis of OP-adducted biomarker proteins has several advantages over the Ellman 
assays or the urinary DAP metabolite analyses. No additional blood draw is required to 
determine subjects’ baseline activity levels, which would eliminate thousands of blood 
draws from agricultural workers before the spray season starts, and avoid the difficulty of 
obtaining multiple blood draws. The MS analyses simply provide an accurate determination 
of the percentage adduction of the active-site serine in biomarker proteins. In addition, 
adducted proteins have a much longer half-life than DAP metabolites, increasing the window 
of time for exposure detection. Additionally, the high sensitivity of MS also provides some 
information about the OP to which the individual was exposed. The use of finger stick/dried 
blood spot analyses significantly simplifies sample collection, shipping and archiving. MS is 
still an emerging field, and implementation of this technology in clinical laboratories is still 
underway. However, thanks to the significant accomplishments obtained in recent years, the 
future of MS as a tool to quantify children’s exposures at any life stage is very promising.
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Figure 1. 
PON1 status plot of 704 subjects identifying 4 individuals (arrows) discordant with respect 
to DNA SNP analysis and those with coding region changes. The 3 PON1192 phenotypes are 
clearly resolved. Arrow 1: PON1Trp194stop allele; arrow 2: suspected of having a partial 
deletion of the coding region; arrow 3: coding region change PON1Asp124missplice; arrow 4: 
coding region change PON1Pro90Leu. Reproduced with permission from Jarvik et al.30
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Figure 2. 
Gene structure of the human PON1 gene showing the 9 coding exons and the frequencies of 
SNPs in the 5′ and 3′ non-coding regions, in introns and exons. Note that there are 
approximately 200 SNPs identified with different frequencies. Modified from Seattle SNPs 
(http://pga.gs.washington.edu/data/pon1/welcome.html).
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Figure 3. 
Individual data points for arylesterase activities in mothers (solid circles) and newborns 
(open circles) for each PON1192 genotype as indicated. Means are indicated by the 
crossbars. Reproduced with permission from Furlong et al.34
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Figure 4. 
Biotransformation of the organophosphate insecticide chlorpyrifos. The chemical structures 
in yellow boxes are dialkylphosphate metabolites. The red box contains organophosphate-
adducted butyrylcholinesterase (BChE).
Marsillach et al. Page 18
Ann Glob Health. Author manuscript; available in PMC 2017 January 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
